Dyne Therapeutics (DYN) Net Cash Flow (2019 - 2026)

Dyne Therapeutics' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$140.2 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 481.05% year-over-year to -$140.2 million; the TTM figure through Mar 2026 stood at $281.3 million (up 40.48% YoY), while the FY2025 annual figure was $458.3 million, up 46.23% from the prior year.
• Net Cash Flow was -$140.2 million for Q1 2026 at Dyne Therapeutics, down from $320.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $336.2 million in Q2 2024 to a low of -$140.2 million in Q1 2026.
• Historically, Net Cash Flow has averaged $32.5 million across 5 years, with a median of $8.9 million in 2022.
• Biggest YoY gain for Net Cash Flow was 2589.4% in 2024; the steepest drop was 1016.35% in 2024.
• A 5-year view of Net Cash Flow shows it stood at $27.2 million in 2022, then slumped by 131.79% to -$8.7 million in 2023, then sank by 1016.35% to -$96.7 million in 2024, then surged by 431.01% to $320.1 million in 2025, then slumped by 143.81% to -$140.2 million in 2026.
• The last three Net Cash Flow figures came in at -$140.2 million (Q1 2026), $320.1 million (Q4 2025), and $88.6 million (Q3 2025), per Business Quant data.